Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate.
Johnson
Nathalie A
NA
Fetni
Raouf
R
Caplan
Stephen N
SN
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D016543:Central Nervous System Neoplasms / Q000134:cerebrospinal fluid* / Q000175:diagnosis / Q000628:therapy; D002908:Chronic Disease; D017809:Fatal Outcome; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000134:cerebrospinal fluid* / Q000175:diagnosis / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012008:Recurrence; D012074:Remission Induction
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate